The following research analysts cover Destiny Pharma:
Brian White, Shore Capital | +44(0)20 7408 4050 |
Karl Keegan, Singer Capital Markets | +44(0)20 7496 3187 |
Adam McCarter, Cavendish Capital Markets | +44(0)20 7220 0500 |
Andy Smith, Equity Development | +44(0)20 7065 2690 |
Dominic Rose, Intron Health | +44(0)20 8156 7791 |
Please click on links below to access coverage published:
Shore Capital Markets
31 January 2024 – Pipeline progress |
|
Cavendish Capital Markets
4 January 2024 – Maximising XF-73 nasal value the priority for 2024 |
|
Equity Development
31 January 2024 – Clinical Development Updates |
|
Intron Health
10 August 2023 – Building An Infection Prevention Powerhouse |
|
Proactive Investors
For further commentary and interviews, please visit the Destiny Pharma page at Proactive Investors on the link above |
|
VOX Markets
For further commentary and interviews, please visit the Destiny Pharma page at Vox Markets on the link above |